Fig 1.
Patients with high solute carrier family 20 member 1 (SLC20A1) expression (SLC20A1high) have poorer clinical outcomes at early tumor stages.
(A-F) Kaplan-Meier analyses comparing the disease-specific survival (DSS) and relapse-free status (RFS) in all patients with breast cancer between those in the SLC20A1high and low SLC20A1 expression (SLC20A1low) groups. (A) DSS in tumor stage I. (B) DSS in tumor stage II. (C) DSS in tumor stage III. (D) RFS in tumor stage I. (E) RFS in tumor stage II. (F) RFS in tumor stage III.
Table 1.
Multivariate Cox regression analyses of disease-specific survival (DSS) and relapse-free status (RFS) in tumor stages I, II or III.
Fig 2.
Patients with high solute carrier family 20 member 1 (SLC20A1) expression (SLC20A1high) have poorer outcomes from early-stage luminal A breast cancer.
(A-F) Kaplan-Meier analyses comparing disease-specific survival (DSS) and relapse-free status (RFS) in patients with luminal A breast cancer between the SLC20A1high and SLC20A1low groups. (A) DSS in tumor stage I. (B) DSS in tumor stage II. (C) DSS in tumor stage III. (D) RFS in tumor stage I. (E) RFS in tumor stage II. (F) RFS in tumor stage III. (G-L) Kaplan-Meier analyses comparing DSS and RFS in patients with luminal B breast cancer between the SLC20A1high and SLC20A1low groups. (G) DSS in tumor stage I. (H) DSS in tumor stage II. (I) DSS in tumor stage III. (J) RFS in tumor stage I. (K) RFS in tumor stage II. (L) RFS in tumor stage III.
Table 2.
Multivariate Cox regression analyses of disease-specific survival (DSS) and relapse-free status (RFS) in patients with luminal A and luminal B breast cancer at tumor stages I, II and III.
Fig 3.
Higher solute carrier family 20 member 1 (SLC20A1) expression (SLC20A1high) confer poorer clinical outcomes in the luminal A and luminal B breast cancer subtypes following endocrine therapy.
(A-D) Kaplan-Meier analyses comparing disease-specific survival (DSS) and relapse-free status (RFS) between the SLC20A1high and low SLC20A1 expression (SLC20A1low) groups in patients with luminal A breast cancer without or with endocrine therapy. (A) DSS in the group without endocrine therapy. (B) DSS in the group with endocrine therapy. (C) RFS in the group without endocrine therapy. (D) RFS in the group with endocrine therapy. (E-H) Kaplan-Meier analyses comparing DSS and RFS between the SLC20A1high and SLC20A1low groups in patients with luminal B breast cancer without or with endocrine therapy. (E) DSS in the group without endocrine therapy. (F) DSS in the group with endocrine therapy. (G) RFS in the group without endocrine therapy. (H) RFS in the group with endocrine therapy.
Table 3.
Comparison of disease-specific survival (DSS) and relapse-free status (RFS) in luminal A and luminal B breast cancer without or with endocrine therapy.
Fig 4.
High solute carrier family 20 member 1 (SLC20A1) expression (SLC20A1high) confer poorer clinical outcomes in patients with luminal A breast cancer at the early stages with endocrine therapy.
(A-D) Kaplan-Meier analyses comparing disease-specific survival (DSS) or relapse-free status (RFS) between the SLC20A1high and low SLC20A1 expression (SLC20A1low) groups amongst patients with stage I luminal A breast cancer without or with endocrine therapy. (A) Comparing DSS of patients without endocrine therapy. (B) Comparing DSS of patients with endocrine therapy. (C) Comparing RFS of patients without endocrine therapy. (D) Comparing RFS of patients with endocrine therapy. (E-H) Kaplan-Meier analyses comparing DSS or RFS between the SLC20A1high and SLC20A1low groups amongst patients with stage II luminal A breast cancer without or with endocrine therapy. (E) Comparing DSS of patients without endocrine therapy, (F) Comparing DSS of patients with endocrine therapy, (G) Comparing RFS of patients without endocrine therapy, (H) Comparing RFS of patients with endocrine therapy. (I-L) Kaplan-Meier analyses comparing DSS or RFS between the SLC20A1high and SLC20A1low groups amongst patients with stage III luminal A breast cancer without or with endocrine therapy. (I) Comparing DSS of patients without endocrine therapy. (J) Comparing DSS of patients with endocrine therapy. (K) Comparing RFS of patients without endocrine therapy. (L) Comparing RFS of patients with endocrine therapy. (I and K) There were insufficient numbers for Kaplan-Meier analysis. N.D. stands for “not determined”.
Fig 5.
There are no significant differences between high solute carrier family 20 member 1 (SLC20A1) expression (SLC20A1high) and low SLC20A1 expression (SLC20A1low) in patients with luminal B breast cancer at each tumor stage undergoing endocrine therapy.
(A-D) Kaplan-Meier analyses comparing disease-specific survival (DSS) or relapse-free status (RFS) between the SLC20A1high and SLC20A1low groups amongst patients with stage I luminal B breast cancer without or with endocrine therapy. (A) Comparing DSS of patients without endocrine therapy. (B) Comparing DSS of patients with endocrine therapy. (C) Comparing RFS of patients without endocrine therapy. (D) Comparing RFS of patients with endocrine therapy. (E-H) Kaplan-Meier analyses comparing DSS or RFS between the SLC20A1high and SLC20A1low groups amongst patients with stage II luminal B breast cancer without or with endocrine therapy. (E) Comparing DSS of patients without endocrine therapy. (F) Comparing DSS of patients with endocrine therapy, (G) Comparing RFS of patients without endocrine therapy. (H) Comparing RFS of patients with endocrine therapy. (I-L) Kaplan-Meier analyses comparing DSS or RFS between the SLC20A1high and SLC20A1low groups amongst patients with stage III luminal B breast cancer without or with endocrine therapy. (I) Comparing DSS of patients without endocrine therapy, (J) Comparing DSS of patients with endocrine therapy, (K) Comparing RFS at patients without endocrine therapy, (L) Comparing RFS of patients with endocrine therapy. (I and K) There were insufficient numbers for Kaplan-Meier analysis. N.D. stands for “not determined”.
Table 4.
Multivariate Cox regression analyses of disease-specific survival (DSS) and relapse-free status (RFS) in patients with luminal A and luminal B without or with endocrine therapy at various tumor stages.
Fig 6.
High solute carrier family 20 member 1 (SLC20A1) expression (SLC20A1high) does not confer poor clinical outcomes in the luminal A and luminal B subtypes following chemotherapy.
(A-D) Kaplan-Meier analyses comparing disease-specific survival (DSS) and relapse-free status (RFS) between the SLC20A1high and low SLC20A1 expression (SLC20A1low) groups amongst patients with luminal A breast cancer without or with chemotherapy. (A) DSS in the group without chemotherapy. (B) DSS in the group with chemotherapy. (C) RFS in the group without chemotherapy. (D) RFS in the group with chemotherapy. (E-H) Kaplan-Meier analyses comparing the DSS or RFS between the SLC20A1high and SLC20A1low groups amongst patients with luminal B breast cancer without or with chemotherapy. (E) DSS in the group without chemotherapy. (F) DSS in the group with chemotherapy. (G) RFS in the group without chemotherapy. (H) RFS in the group with chemotherapy.
Table 5.
Multivariate Cox regression analyses of disease-specific survival (DSS) or relapse-free status (RFS) in patients with luminal A and luminal B breast cancer without/with chemotherapy.
Fig 7.
High solute carrier family 20 member 1 (SLC20A1) expression (SLC20A1high) confers higher recurrence incidence rates compared with patients with low SLC20A1 expression (SLC20A1low) after long periods of time in both luminal A and luminal B subtypes.
(A-B) Pie charts of the recurrent period and number of patients in the SLC20A1high and SLC20A1low groups amongst those with luminal A or luminal B breast cancer. (A) Patients with SLC20A1high (left) and SLC20A1low (right) luminal A. (B) Patients with SLC20A1high (left) and SLC20A1low (right) luminal B. (C-D) Line graphs showing the recurrence incidence rates of patients in the SLC20A1high and SLC20A1low luminal A or luminal B groups every 5 years with or without endocrine therapy. P-values were calculated using the statistic based on normal distribution and corrected using the Holm method. The incidence rate ratio was calculated as the ratio of the recurrence incidence rate of SLC20A1high to that of SLC20A1low. The 95% confidence interval and the number of patients were shown on the right sides. (C) Patients with luminal A. (D) Patients with luminal B.